Technology
Health
Pharmaceutical

Evolus

$16.99
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.58 (-3.31%) Today
+$0.05 (0.30%) After Hours

Why Robinhood?

You can buy or sell Evolus and other stocks, options, ETFs, and crypto commission-free!

About

Evolus, Inc. Common Stock, also called Evolus, is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. Read More It offers products under the brand of Jeuveau. The company was founded in November, 2012 and is headquartered in Newport Beach, CA.

Employees
70
Headquarters
Newport Beach, California
Founded
2012
Market Cap
478.04M
Price-Earnings Ratio
Dividend Yield
Average Volume
670.13K
High Today
$17.77
Low Today
$16.61
Open Price
$17.77
Volume
668.67K
52 Week High
$39.50
52 Week Low
$10.22

Collections

Technology
Health
Pharmaceutical
Medical
2018 IPO
US
North America

News

Seeking AlphaMay 16

Evolus down 10% premarket on 4M-share stock sale

Evolus (NASDAQ:EOLS) slumps 10% premarket on light volume in reaction to the sale of 4M common shares by ALPHAEON. Underwriter Morgan Stanley will have the option to buy up to 600K additional shares.

912
Seeking AlphaMay 15

Evolus And The U.S. Cosmetic Neurotoxin Landscape

EOLS is in the midst of launching their Botox alternative in North America and will be competing with Botox, Xeomin and Dysport. Evolus (EOLS) is a one drug company that is gearing up to enter the personal aesthetics arena. They look to compete against the market leader, Allergan (AGN), with their own version of Botox, which will be branded as Jeuveau in the US. They have also recently received a positive opinion from the CHMP in the EU for their product and are awaiting the final decision, which should co...

752
Yahoo FinanceMay 8

Botox Competitor Aims to Take Market Share as Allergan Stumbles

(Bloomberg) -- An upstart company with a competitor to Allergan Plc’s Botox has its eye on becoming the next wrinkle treatment of choice.

513

Earnings

Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.